Literature DB >> 26505803

Local Recurrence Significantly Increases the Risk of Metastatic Uveal Melanoma.

.   

Abstract

PURPOSE: To assess of the effect of local recurrence of uveal melanoma on metastasis using a multicenter international tumor registry.
DESIGN: Retrospective study using an online tumor registry. PARTICIPANTS: Patients with uveal melanoma diagnosed between 2001 and 2011.
METHODS: A committee was formed to create uveal melanoma patient-specific data fields. Ten subspecialty ophthalmic oncology centers from 4 continents shared data. Patient selection criteria included diagnosis of uveal melanoma and adequate records to allow tumor staging by American Joint Committee on Cancer (AJCC) criteria and follow-up for metastatic melanoma. MAIN OUTCOME MEASURES: Local tumor recurrence and metastatic uveal melanoma.
RESULTS: Of 3809 total entries, 3217 patients with ciliary body and choroidal (CBC) melanoma and 160 with iris melanoma were evaluated. There was a median follow-up of 3.7 years (95% confidence interval [CI], 3.5-3.8). One hundred fifty-two patients (4.7%) with CBC melanoma experienced local recurrence, with a cumulative incidence of 11%. Kaplan-Meier point estimates for remaining free of local recurrence were 99% (95% CI, 99-99) at 1 year, 93% (95% CI, 92-94) at 5 years, and 89% (95% CI, 86-91) at 10 years. Five- and 10-year metastasis-free Kaplan-Meier estimates for the recurrence-free group were 87% (95% CI, 86-89) and 82% (95% CI, 79-84), and those for the local recurrence group were 71% (95% CI, 62-78) and 62% (95% CI, 49-72). The difference between these 2 groups was statistically significant (P < 0.001). Furthermore, local tumor recurrence increased the risk of metastasis by a hazard ratio (HR) of 6.28 (95% CI, 4.4-8.9; P < 0.001). Local recurrence was detected up to 9.8 years after treatment. Extrascleral extension also was associated with local recurrence (HR, 3.2; 95% CI, 1.5-6.7; P = 0.003), but higher AJCC T-size category was not (P = 0.63). Five patients (n = 5/161 [3.1%]) with iris melanoma demonstrated local recurrence and 1 metastasized.
CONCLUSIONS: International multicenter data sharing was used to evaluate the effect of local tumor recurrence on metastatic rate. In that local tumor recurrence was associated with a significantly higher risk of systemic metastasis, effective initial treatment and long-term surveillance of treated uveal melanoma patients is necessary.
Copyright © 2016 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26505803     DOI: 10.1016/j.ophtha.2015.09.014

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  31 in total

1.  A non-contiguous recurrence of the ciliary body melanoma-is cataract surgery a risk factor?

Authors:  Biljana Kuzmanović Elabjer; Mladen Bušić; Mirjana Bjeloš; Daliborka Miletić; Nenad Vukojević
Journal:  Int J Ophthalmol       Date:  2020-04-18       Impact factor: 1.779

2.  Parthenolide inhibits the proliferation and induces the apoptosis of human uveal melanoma cells.

Authors:  Song-Tian Che; Li Bie; Xu Li; Hui Qi; Peng Yu; Ling Zuo
Journal:  Int J Ophthalmol       Date:  2019-10-18       Impact factor: 1.779

3.  Salvage proton beam therapy for recurrent iris melanoma: outcome and side effects.

Authors:  Aline I Riechardt; Julian P Klein; Dino Cordini; Jens Heufelder; Matus Rehak; Ira Seibel; Antonia M Joussen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-02-20       Impact factor: 3.117

4.  Juxtapapillary and circumpapillary choroidal melanoma: globe-sparing treatment outcomes with iodine-125 notched plaque brachytherapy.

Authors:  John V Hegde; Tara A McCannel; Colin A McCannel; James Lamb; Pin-Chieh Wang; Darlene Veruttipong; Robert Almanzor; D Jeffrey Demanes; Mitchell Kamrava
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-06-09       Impact factor: 3.117

5.  Outcomes following Notched Ruthenium-106 Plaque Brachytherapy for Juxtapapillary Choroidal Melanomas.

Authors:  Manvi Manu Sobti; Magdalena Edington; Julie Connolly; David J McLernon; Stefano Schipani; Diana Ritchie; Paul Cauchi; Vikas Chadha
Journal:  Ocul Oncol Pathol       Date:  2021-08-23

6.  Ruthenium-106 plaque radiotherapy for uveal melanoma: analysis of tumor dimension and location on anatomical and functional results.

Authors:  Reza Mirshahi; Ahad Sedaghat; Ramin Jaberi; Zohreh Azma; Mehdi Mazloumi; Masood Naseripour
Journal:  BMC Ophthalmol       Date:  2022-07-16       Impact factor: 2.086

Review 7.  Iodine-125 Brachytherapy for Uveal Melanoma: A Systematic Review of Radiation Dose.

Authors:  Jose J Echegaray; Nikolaos E Bechrakis; Nakul Singh; Claudine Bellerive; Arun D Singh
Journal:  Ocul Oncol Pathol       Date:  2017-02-08

8.  Uveal Melanoma Cell Seeding after Transretinal Tumor Biopsy?

Authors:  Konrad R Koch; Ahmed M Hishmi; Monika Ortmann; Ludwig M Heindl
Journal:  Ocul Oncol Pathol       Date:  2017-01-26

9.  Orbital recurrence of iris melanoma 21 years after enucleation.

Authors:  Emilie Bergeron; Nadia Lihimdi; Dan Bergeron; Solange Landreville
Journal:  BMJ Case Rep       Date:  2017-09-07

10.  Multifocal Intraretinal Tumour Deposits following Treatment of an Ipsilateral Choroidal Melanoma.

Authors:  Aaron Jamison; Julie Connolly; Paul Cauchi; Chee Thum; Vikas Chadha
Journal:  Ocul Oncol Pathol       Date:  2020-10-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.